Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2010

Open Access 01-12-2010 | Research

Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome

Authors: Steve Heymann, Suzette Delaloge, Arslane Rahal, Olivier Caron, Thierry Frebourg, Lise Barreau, Corinne Pachet, Marie-Christine Mathieu, Hugo Marsiglia, Céline Bourgier

Published in: Radiation Oncology | Issue 1/2010

Login to get access

Abstract

Background

There are no specific recommendations for the management of breast cancer patients with germ-line p53 mutations, an exceptional genetic condition, particularly regarding postoperative radiotherapy. Preclinical data suggested that p53 mutations conferred enhanced radiosensitivity in vitro and in vivo and the few clinical observations showed that Li-Fraumeni families were at a higher risk of secondary radio-induced malignancies.

Methods

We reviewed a cohort of patients with germ-line p53 mutations who had been treated for breast cancer as the first tumor event. We assessed their outcome and the incidence of secondary radio-induced malignancies.

Results

Among 47 documented Li-Fraumeni families treated from 1997 to 2007 at the Institut Gustave Roussy, 8 patients had been diagnosed with breast cancer as the first tumor event. Three patients had undergone conservative breast surgery followed by postoperative radiotherapy and five patients had undergone a mastectomy (3 with postoperative radiotherapy). Thus, 6/8 patients had received postoperative radiotherapy. Median follow-up was 6 years. Median age at the diagnosis of the primary breast cancer was 30 years. The histological characteristics were as follows: intraductal carcinoma in situ (n = 3), invasive ductal carcinoma (n = 4) and a phyllodes tumor (n = 1). Among the 6 patients who had received adjuvant radiotherapy, the following events had occurred: 3 ipsilateral breast recurrences, 3 contralateral breast cancers, 2 radio-induced cancers, and 3 new primaries (1 of which was an in-field thyroid cancer with atypical histology). In contrast, only one event had occurred (a contralateral breast cancer) among patients who had not received radiation therapy.

Conclusions

These observations could argue in favor of bilateral mastectomy and the avoidance of radiotherapy.
Appendix
Available only for authorised users
Literature
1.
Li FP, Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969, 71: 747-752.CrossRefPubMed
2.
Gonzalez KD, Noltner KA, Buzin CH, et al.: Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009, 27: 1250-1256. 10.1200/JCO.2008.16.6959CrossRefPubMed
3.
Li FP, Fraumeni JF Jr, Mulvihill JJ, et al.: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48: 5358-5362.PubMed
4.
Varley JM: Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003, 21: 313-320. 10.1002/humu.10185CrossRefPubMed
5.
Olivier M, Goldgar DE, Sodha N, et al.: Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003, 63: 6643-6650.PubMed
6.
Lee SB, Kim SH, Bell DW, et al.: Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res 2001, 61: 8062-8067.PubMed
7.
Varley J: TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol 2003, 222: 117-129.PubMed
8.
9.
Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408: 307-310. 10.1038/35042675CrossRefPubMed
10.
Vousden KH: Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002, 1602: 47-59.PubMed
11.
12.
Wang QE, Zhu Q, Wani MA, et al.: Tumor suppressor p53 dependent recruitment of nucleotide excision repair factors XPC and TFIIH to DNA damage. DNA Repair (Amst) 2003, 2: 483-499. 10.1016/S1568-7864(03)00002-8CrossRef
13.
Fei P, El-Deiry WS: P53 and radiation responses. Oncogene 2003, 22: 5774-5783. 10.1038/sj.onc.1206677CrossRefPubMed
14.
Bougeard G, Brugieres L, Chompret A, et al.: Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 2003, 22: 840-846. 10.1038/sj.onc.1206155CrossRefPubMed
15.
Kony SJ, de Vathaire F, Chompret A, et al.: Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997, 350: 91-95. 10.1016/S0140-6736(97)01116-1CrossRefPubMed
16.
Hisada M, Garber JE, Fung CY, et al.: Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998, 90: 606-611. 10.1093/jnci/90.8.606CrossRefPubMed
17.
Nutting C, Camplejohn RS, Gilchrist R, et al.: A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? Clin Oncol (R Coll Radiol) 2000, 12: 300-304.
18.
Limacher JM, Frebourg T, Natarajan-Ame S, et al.: Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001, 96: 238-242. 10.1002/ijc.1021CrossRefPubMed
19.
Salmon A, Amikam D, Sodha N, et al.: Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol) 2007, 19: 490-493.CrossRef
20.
Bollet MA, Sigal-Zafrani B, Mazeau V, et al.: Age remains the first prognostic factor for loco-regional breast cancer recurrence in young ( < 40 years) women treated with breast conserving surgery first. Radiother Oncol 2007, 82: 272-280. 10.1016/j.radonc.2007.01.001CrossRefPubMed
21.
Prise en charge du cancer du sein infiltrant de la femme non ménopausée Oncologie 2009, 11: 507-532. 10.1007/s10269-009-1818-6
22.
Livasy CA, Karaca G, Nanda R, et al.: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006, 19: 264-271. 10.1038/modpathol.3800528CrossRefPubMed
23.
Veronesi U, Marubini E, Del Vecchio M, et al.: Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995, 87: 19-27. 10.1093/jnci/87.1.19CrossRefPubMed
24.
Fowble BL, Schultz DJ, Overmoyer B, et al.: The influence of young age on outcome in early stage breast cancer. Int J Radiat Oncol Biol Phys 1994, 30: 23-33.CrossRefPubMed
25.
Rubino C, de Vathaire F, Shamsaldin A, et al.: Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003, 89: 840-846. 10.1038/sj.bjc.6601138PubMedCentralCrossRefPubMed
26.
Delia D, Goi K, Mizutani S, et al.: Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene 1997, 14: 2137-2147. 10.1038/sj.onc.1201050CrossRefPubMed
27.
Mitchel RE, Jackson JS, Carlisle SM: Upper dose thresholds for radiation-induced adaptive response against cancer in high-dose-exposed, cancer-prone, radiation-sensitive Trp53 heterozygous mice. Radiat Res 2004, 162: 20-30. 10.1667/RR3190CrossRefPubMed
28.
Tinat J, Bougeard G, Baert-Desurmont S, et al.: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27: e108-109. author reply e110 10.1200/JCO.2009.22.7967CrossRefPubMed
Metadata
Title
Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome
Authors
Steve Heymann
Suzette Delaloge
Arslane Rahal
Olivier Caron
Thierry Frebourg
Lise Barreau
Corinne Pachet
Marie-Christine Mathieu
Hugo Marsiglia
Céline Bourgier
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2010
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-5-104

Other articles of this Issue 1/2010

Radiation Oncology 1/2010 Go to the issue

Research

Evaluation of volumetric modulated arc therapy (VMAT) with Oncentra MasterPlan® for the treatment of head and neck cancer

Case report

A case report of pseudoprogression followed by complete remission after proton-beam irradiation for a low-grade glioma in a teenager: the value of dynamic contrast-enhanced MRI

Research

Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21

Research

Factors of influence upon overall survival in the treatment of intracranial MPNSTs. Review of the literature and report of a case

Research

The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation

Research

Semi-robotic 6 degree of freedom positioning for intracranial high precision radiotherapy; first phantom and clinical results